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Abstract
A slowly progressive Heymann nephritis (SPHN) was induced in three groups of rats by weekly injections of a chemically
modiﬁed renal tubular antigen in an aqueous medium. A control group of rats received the chemically unmodiﬁed version of
the antigen in an aqueous solution. One group of SPHN rats were pre- and post-treated with weekly injections of IC made up
of rKF3 and rarKF3 IgM antibody at antigen excess (MIC) (immune complexes [ICs] containing sonicated ultracentrifuged
[u/c] rat kidney fraction 3 [rKF3] antigen and IgM antibodies speciﬁc against the antigen, at slight antigen excess). One group
of SPHN rats were post-treated with MIC 3 weeks after the induction of the disease and one group of SPHN animals received
no treatment. The control group of rats received pre- and post-treatment with sonicated u/c rKF3.
The incidence of immune-complex glomerulonephritis (ICGN) in the untreated SPHN rats was 87%, in the pre- and post-
treated animals 13%, and in the post-treated-only rats 20%. Rats receiving sonicated ultracentrifuged rKF3 antigen did not
develop ICGN.
The present experiment demonstrates that the development of SPHN can be not only prevented but also effectively
terminated by our newly developed modiﬁed vaccination technique.
Keywords: Autoimmunity, modiﬁed vaccination technique, non-pathogenic IgM autoantibody, pathogenic IgG autoantibody,
slowly progressive Heymann nephritis
Abbreviations: aab, autoantibody; FCA, Freund’s complete adjuvant; GBM, glomerular; FX1A, nephritogenic antigen;
H&E, hematoxylin and eosin; HN, Heymann nephritis; IC, immune complex; ICGN, immune complex glomerulonephritis; IP,
intraperitoneal; MIC, IC made up of rKF3 and rarKF3 IgM antibody at antigen excess; rKF3, rat kidney fraction 3; rarKF3, rat
anti-rKF3; SPHN, slowly progressive Heymann nephritis; u/c, ultracentrifuged
Introduction
Autoimmune diseases in humans are treated mainly
with immunosuppressive agents. These agents are
non-speciﬁc in their action: they depress the overall
function of the immune system and cause numerous
side effects.
However, newer approaches have shown promise.
For example, orally or nasally administering disease-
related antigens has appeared in certain studies to slow
down immunopathological events rather than exacer-
bating them (al Sabbagh et al. 1994, Yoshino et al.
1995, Weiner 1997, Hussell and Humphreys 2002).
Administration of pooled immunoglobulin obtained
from the sera of hundreds of normal blood donors has
also seemed to have beneﬁcial effects in patients with
autoimmune disorders (Imbach et al. 1981, Becker
et al. 1995, Mobini et al. 1995, Jolles 2002). Recently
discovered medications that are able to eliminate
autoreactive B cells and thereby suppress pathogenic
autoimmune events are also promising treatment
options (Saleh et al. 2000, Quartier et al. 2001).
Strictly speaking, antigen-speciﬁc down-regulation
of undesirable pathogenic autoimmune responses
(especially when autoimmune disease-causing pro-
cesses have been ascertained) had not yet been
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autoimmune kidney disease in rats called slowly
progressive Heymann nephritis (SPHN) (Barabas
et al. 2004a, Barabas and Lafreniere 2005). The goal
for the last few years has been to introduce the relevant
self antigen to the immune system in such a way as to
provokethedesireddown-regulatoryeffectonimmune
response against self. Current antigen delivery systems
havenotbeenthemostsuitably designed techniquesto
prevent and/or treat autoimmune disorders.
Recently, we have discovered and implemented a
new antigen delivery system using a new vaccination
methodology. We call the new technique “modiﬁed
vaccination” (patent pending), since its effectiveness
in evoking a desirable immune response in the injected
animal is based on immune-inducing components that
are employed in active and passive immunizations. We
have found that immune complexes made of antigens
combined with speciﬁc antibodies at slight antigen
excess can produce in the vaccinated host the same
class of immunoglobulin with the same antibody
activity against the target antigen as occurs in the
inoculum itself. This vaccination technique is able to
evoke a powerful predetermined immune response in
the host. We have also observed that the new
vaccination protocol can be used both prophylactically
and therapeutically. We believe that this modiﬁed
vaccination technique holds the promise of changing
or redirecting immune function for the beneﬁt of the
vaccinated host in several human medical conditions
that do not yet have satisfactory treatments.
The aim of the present experiment was to
implement the modiﬁed vaccination technique in a
newly developed autoimmune kidney disease, called
SPHN (Barabas et al. 2004b), where immunopatho-
logical events are slowly progressive, just as in some
“naturally occurring” autoimmune diseases in
humans (Arbuckle et al. 2003).
Materials and methods
Experimental groups
Two-month-old male Sprague Dawley rats, known to
develop Heymann nephritis (HN), were used in the
experiment. Prior to randomly allocating them to the
four experimental groups they were earmarked for
individual identiﬁcation. All invasive procedures were
carried out on Isoﬂurane anaesthetized rats. At the
end of the experiment at 26 weeks, the rats were
euthanized by intraperitoneal (IP) injection of
Euthanyl (180mg/kg body weight, MTC Pharmaceu-
ticals, Cambridge, ON).
Control group
Fifteen rats were injected intraperitoneally with 30mg
rKF3 antigen every week till the end of the
experiment. From 3 weeks after the ﬁrst injection of
rat kidney fraction 3 (rKF3) they received additional
weekly sonicated u/c 100mg rKF3 antigen intraperi-
toneally (always 3 days post 30mg rKF3 injections) for
the ﬁrst 10 weeks, and then 300mg sonicated u/c rKF3
for the remaining weeks, in 0.2ml saline.
Test group 1
Fifteen rats were pre- and post-treated intraperitone-
ally with IC made up of rKF3 and rarKF3 IgM
antibody at antigen excess (MIC) (containing
immune complexs (ICs) made up of 30mg rKF3
antigen and rat anti-rKF3 IgM antibody, at slight
antigen excess) 3 weeks before the start of the
experiment proper, and then at weekly intervals till the
end of the experiment. To induce the disease, rats
received weekly IP injections of 100mg azo sonicated
u/c rKF3 for the ﬁrst 10 weeks, and then 300mg azo-
sonicated u/c rKF3 for the remaining weeks, in 0.2ml
saline.
Test group 2
Fifteen rats were post-treated with MIC 3 weeks after
the disease-inducing antigen injections, administered
exactly the same way as in test group 1 rats.
Test group 3
Fifteen rats received weekly injections of only the
disease-causing antigens, at the same time as test
group 1 and 2 rats.
Preparation of rKF3, sonicated u/c rKF3, azo-sonicated
ultracentrifuged rKF3 and azo-sonicated rKF3 antigens
These antigen preparations were made using Sprague
Dawley rat kidney fraction 3 by methods and
procedures previously described (Barabas et al. 2003).
Urinary protein estimation
Twenty-four-hour specimens of urine were collected
from individual rats in metabolic cages before the start
of the experiment and at weeks 2, 4, 7, 8, 9, 20, 21 and
26. The protein content of the urine samples was
determined by the biuret method of Weichselbaum
(1946) using a Spectronic Genesis 5 Spectophoto-
meter at 540nm.
Light microscopy, direct immunoﬂuorescence and
electronmicroscopy on renal cortical samples
Kidney biopsies were obtained 8 weeks after the
induction of SPHN from 15 rats pre- and post-treated
with MIC, and from 5 rats post-treated only. Biopsies
were also obtained from 15 untreated SPHN rats and
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were stained by the direct ﬂuorescence antibody tests
for rat IgG employing appropriate dilutions of Alexa
Fluor 488-labeled goat anti-rat IgG (H þ L) (Mol-
ecular Probes Inc., Eugene, OR). At the end of the
experiment, histological specimens were obtained for
H&E and methenamine silver staining from kidney
samples of 9 of each 15 test group rats and 5 of the 15
control group rats. Representative kidney biopsy
samples were also processed for electron microscopy.
Preparation of rat anti-rat KF3 IgM and immune
complexes (designated as MIC)
Production of rat anti-rat KF3 IgM antibody was
carried out in rats by repeated IP injections of rKF3
antigen in an aqueous medium. Immune complexes,
designated as MIC (made up of rKF3 antigen and
rarKF3 IgM antibody at slight antigen excess), were
prepared prior to the injections of test group 1 and 2
rats as previously described (Barabas et al. 2004a,
Barabas and Lafreniere 2005).
Grading of glomerular lesions resulting from deposition
of rat IgG
The intensity of ﬂuorescence in the glomeruli was
determined on a scale of 0–4 þ by a semi-
quantitative method at a constant microscope setting.
The amount of ﬂuorescent material in the glomeruli
was also graded. Grade 0 lesions had no glomerular
deposits. Most of the ICs in the glomerular capillaries
of rats with immune complex glomerulonephritis
(ICGN) were made up of small closely packed
deposits. The differences in the amounts of single-
layered deposits were quantiﬁed on a 0–4 þ scale.
The single layer of deposit around the glomerular
capillaries indicated that the lesions were not too
advanced.
Results
Proteinuria
One pre-treatment sample of urine was obtained from
each group of rats to ﬁnd out if pre-treatment with
rKF3 or MIC would effect protein excretion. The
average proteinuria levels of the four groups of rats, as
ascertained from the pre-SPHN induction urine
samples, was between 5 and 6mg per 24h. Results
obtained at the end of the experiment from individual
groups of rats similarly showed no signiﬁcant change
in protein excretion levels, being between 7 and 10mg
per 24h on average. Thus, neither pre-/post- or post-
treatment with MIC nor injection of azo-rKF3 or
rKF3 antigens signiﬁcantly altered protein excretion
during the 26-week experimental period.
Light microscopy
Hematoxylin and eosin Hematoxylin and eosin
(H&E) kidney sections of variously treated rats
showed no differences in glomerular cell counts. On
average these ranged from 48 to 51 cells per
glomerulus in each of the four experimental groups
of rats. Methenamine silver-stained kidney sections
similarly revealed no detectable changes in the
glomerular capillary blood vessels (Figure 1), except
in the two rats with the highest grade lesions. These
rats, and one of them in particular, showed numerous
vaccuolations in their glomerular capillary loops,
revealing the early changes typically observed in HN
kidney lesions.
Direct ﬂuorescence antibody test results
Rat kidney biopsies obtained 8 weeks after the
induction of SPHN showed the following: in the
untreated group of rats all except one rat (14 of 15)
had detectable beaded deposits staining for rat IgG,
mainly with faint ﬂuorescence, along the glomerular
capillary loops. The lesions were considered to be of
low grade. In the pre-/post-treated rats, 12 out of 15
had no detectable deposits in the glomeruli. The three
kidney specimens which did stain showed small, faint,
sparsely distributed deposits. Only ﬁve biopsies were
obtained (of 15 animals) from the post-treated group
of rats. Three kidney specimens showed glomerular
deposits that were mostly faint and linear but in some
areas small and beaded, and two samples were
completely negative. None of the four kidney samples
obtained from the rKF3 injected rats had any
glomerular deposits.
At the end of the experiment kidney samples from
each rat were also stained for the presence of rat IgG.
The incidence of SPHN and ﬂuorescence-graded
Figure 1. Evenly thin glomerular capillary loops show no
morphological changes in the kidney sections of test and control
group rats. PASM stained section.
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noted that 13 of 15 rats in the SPHN untreated rats
had detectable glomerular deposits (Figure 2), while
in the pre-/post- and post-treated-only rats only 2 of
15 and 3 of 15, respectively, had beaded deposits
(Figure 3—Left). Rats injected with rKF3 antigen had
no deposits in the glomeruli (Figure 3—Right).
The table presenting the grade scores clearly shows
that both pre-/post-treatment and post-treatment only
greatly prevented the occurrence of glomerular
deposits.
Electron microscopy
Ultrathin rat kidney sections with no beaded
depositions of rat IgG in the glomeruli by ﬂuorescent
antibody tests also showed no ultrastructural changes
(Figures 4 and 5). Animals with low ﬂuorescence
grades for rat IgG presence in the glomeruli had
detectable small deposits on the epithelial side of the
glomerular basement membrane. As the ﬂuorescence
grades increased, the size of the deposits also
increased. The most severe glomerular lesions were
observed in the kidneys of untreated SPHN rats
(Figure 6). In these animals, small to medium-sized
deposits were observed on the epithelial side of the
glomerular basement membrane (GBM). Epithelial
cell foot processes showed fusion in relation to the
larger deposits. A few of the pre-/post-treated and
post-treated-only rat kidneys had mild glomerular
lesions but most of them, just like the rKF3 antigen
injected rats (Figure 7), had no detectable ultra-
structural kidney alterations.
Discussion
HN is an experimental autoimmune kidney disease of
rats.Itisinitiatedandmaintainedbythedevelopmentof
pathogenic IgG autoantibodies (aabs) following IP
injections of renal tubular antigenic preparations
(FX1A, rKF3, etc.) incorporated mainly in Freund’s
completeadjuvant(FCA)(Heymannetal.1959,Grupe
and Kaplan 1969, Barabas et al. 2003). A similar more
slowly progressive HN called SPHN can also be
established by two different methods described by
Barabas and associates (Barabas et al. 2003, 2004b).
SPHNisalsoinducedbythedevelopmentofpathogenic
aabs, but because the nephritogenic antigen is
introduced inAlum or ina chemically modiﬁed format,
the initiation and progression of the disease is
considerably slower (Barabas et al. 2003, 2004b). In
many ways, especially when the chemically modiﬁed
nephritogenic antigen is administered in an aqueous
medium, the slow development of the autoimmune
disease resembles spontaneously occurring auto-
immune-inducing events in humans (Arbuckle et al.
2003).TheslowdevelopmentofSPHNallowssufﬁcient
time to better study the immunopathological events
which contribute to disease progression (Barabas et al.
2003). Moreover, there is a better chance in SPHN to
intervene and downregulate or even terminate auto-
immune disease-causing events (Barabas et al. 2004a,
Barabas and Lafreniere 2005). Previous attempts to
treat HN with immunosuppressive agents either before
orafteritsinductionresultedinnosigniﬁcantchangesin
thethreemostimportantaspectsofthedisease(Barabas
et al. 1970, Kupor et al. 1976, Cattran 1988,
Matsukawa et al. 1992, Yokoyama et al. 1999). In
these experiments reductions in proteinuria, decreases
in circulating pathogenic IgG aab levels and morpho-
Figure 2. Kidney section of an SPHN untreated rat stains for rat
IgG in the glomerular capillary loops with a diffuse beaded pattern
of ﬂuorescence by a direct ﬂuorescence antibody test. The
Bowman’s capsule and the tubular basement membrane also stain
with beaded deposits (white arrow).
Figure 3. Kidney sections of pre-/post-induction and post-
induction-only treated SPHN rats (left) and of rKF3 antigen
injected rats (right) show no depositions of rat IgG in the glomerular
capillaries by direct ﬂuorescence antibody testing (overexposed
pictures).
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in the epithelial cells ( £ 7500). CL, capillary-loop; D, deposit; En, endothelial cell; Ep, epithelial cell; Fp, foot process; GBM, glomerular
basement membrane; MES, mesangial cell.
Figure 5. Glomerular capillary loop of an SPHN post-treated-only rat. Evenly thin GBM, well preserved foot processes, and epithelial cells
opposite the GBM show no morphological changes ( £ 25,000). CL, capillary-loop; Ep, epithelial cell; Fp, foot process; GBM, glomerular
basement membrane.
Figure 6. Glomerular capillary loop of an SPHN untreated rat. Small to large osmiophilic deposits are partially surrounded by BM-like
material on the epithelial side of the minimally thickened GBM. Foot processes are fused opposite the deposits and the epithelial cell
cytoplasm over the deposits shows mild signs of osmiophilia ( £ 22,500). BM, basement membrane; CL, capillary-loop; D, deposit;
Ep, epithelial cell; GBM, glomerular basement membrane.
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been several attempts lately to intervene more speciﬁ-
cally with immune events in order to suppress disease-
causing processes. To our knowledge none of these
techniques have so far been speciﬁc enough to cause
substantial reductions in disease progression without
signiﬁcant side effects.
Our modiﬁed vaccination technique, on the other
hand, is expected to have a major impact, far beyond
the downregulation of our experimental autoimmune
kidney disease, on the treatment of many human
autoimmune diseases that are mediated by pathogenic
aabs as well. Utilizing the observations of Grabar
(1957, 1965) and the very extensive work of Weir and
associates (Pinckard and Weir 1966, Weir 1966, Weir
et al. 1966, Elson and Weir 1967, Weir and Pinckard
1967,WeirandElson1969),wherein,itwasnotedthat
released intracytoplazmic components are assisted in
theirremovalfromthecirculationbyspeciﬁcIgMaabs,
we set out to ﬁnd out if a speciﬁc increase in IgM aab
production against nephritogenic autoantigens was
able to remove or block circulating modiﬁed and
unmodiﬁednephritogenicantigens.Aspeciﬁcincrease
in IgM aab production might, by removing nephrito-
genic antigens from the circulation, even terminate
pathogenic IgG aab production.
We have recently shown that immuno-pathological
events can be down-regulated by injections of MIC
(containing the native nephritogenic antigen and
speciﬁc IgM antibody against it at a slight antigen
excess) in SPHN rats (Barabas et al. 2004a, Barabas
and Lafreniere 2005). We maintain that the down-
regulatory effect of MIC is due to its ability to
speciﬁcally up-regulate IgM aab production against
the nephritogenic aags (modiﬁed or unmodiﬁed).
Increased production of IgM aabs results in an
unusually high level of circulating IgM aabs, which are
able to assist in the removal of nephritogenic antigens
and thereby prevent further production of pathogenic
disease-causing IgG aabs.
In the present experiment, we investigated whether
the injected MIC could inﬂuence the course of a
milder form of SPHN (Barabas et al. 2004b) in pre-/
post-treated and post-treated-only rats. SPHN
untreated and rKF3 antigen injected rats were also
included in the experiment. During the 26-week
experimental period none of the treated or untreated
SPHN rats or the control rats developed proteinurias.
The low proteinuria results suggested that the
glomerular lesions observed by histology, direct
ﬂuorescence antibody tests and electron microscopy
would not be too severe, and our ﬁndings accorded
with this prediction.
Experimental results at the end of the experiment at
26 weeks clearly revealed that pre-/post-induction
treatment and post-induction-only treatment with
MIC can substantially reduce the incidence and
severity of the developing autoimmune disease in rats,
to 13 and 20% ICGN occurrence in our test groups,
respectively, compared to an 87% incidence in our
untreated rats (Table I). This experiment also proved
once more that the continual injection of unmodiﬁed
renal tubular antigen rKF3 will not cause disease
(Barabas et al. 2004b). It had also been shown earlier
that the continuous release of “unmodiﬁed” intracy-
toplazmic components following cell death will
maintain only non-pathogenic IgM aab production
and not pathogenic IgG aab production in normal
physiological conditions (Weir et al. 1966, Weir and
Pinckard 1967).
Figure 7. Glomerular capillary loops of a control rKF3 antigen-injected rat. The glomerular capillary loop and its related structures show no
morphological alterations ( £ 12,500). CL, capillary-loop; En, endothelial cell; Ep, epithelial cell; Fp, foot process; GBM, glomerular
basement membrane.
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able to terminate the immunopathological events
that led towards full-blown autoimmune diseases
characterized by structural and functional changes in
the target organ. Our unique vaccination technique
therefore represents a signiﬁcant breakthrough. As we
have also shown in previous experiments (Barabas
et al. 2004a, Barabas and Lafreniere 2005), this
technique is able, by the injection of ICs called MICs
(which contain the relevant immune response-
inducing components), to initiate in the injected
host the production of the same class of antibody
with the same speciﬁcity against the antigen that
resides in the injected IC itself. The subsequent
development of IgM aabs speciﬁc against the target
antigen assists in the catabolism of both the modiﬁed
(injected) and unmodiﬁed (released from renal
tubules) antigens present in the circulation. By
reducing and in most cases completely eliminating
the modiﬁed antigen from the circulation, the
production of tissue-damaging pathogenic IgG aabs
is prevented. We believe that our experiments
represent the ﬁrst time that a treatment modality
has been able to speciﬁcally affect the autoimmune
disease-causing events and thereby result in the
prevention and/or termination of an experimental
autoimmune kidney disease. Unlike presently avail-
able treatments, this new vaccination technique,
when its IC components are properly assembled and
employed, will not interfere with the overall function
of the immune system, and nor will it cause side
effects.
This modiﬁed vaccination technique, as we have
observed in our present and previous experiments,
holds the promise of providing a chance for vaccinat-
ing both prophylactically and therapeutically against
both exogenous and endogenous source derived
antigens. Our newly implemented modiﬁed vacci-
nation technique could in the very near future provide
better treatment options for curing autoimmune
disorders, chronic infections and even cancer.
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